Apple Charms Trump with Extra $100B U.S. Investment, Eli Lilly's New Obesity Pill Underwhelms
The Rundown
00:00
Market Reactions: Eli Lilly's Weight Loss Pill Disappointment and DoorDash's Success
This chapter explores recent trends in the pharmaceutical and tech industries, highlighting Eli Lilly's mixed results and DoorDash's stock surge. It contrasts these developments with Airbnb's challenges and Intel's stock decline amid political controversies.
Transcript
Play full episode
